Clinical trial NCT02731469: Study of Pharmacokinetics, Pharmacodynamics, Safety of BCD-131 Compared to Mircera and Aranesp in Healthy Volunteers
Official title: Clinical Study of the Pharmacokinetics, Pharmacodynamics, Tolerability, Safety and Immunogenicity of BCD-131 Compared to Mircera and Aranesp in Healthy Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Reticulocyte Count
Lead sponsor: Biocad
Sponsor class: INDUSTRY
First posted: 2016-04-07
Enrollment: 45
Sex: MALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: BCD-131-1 is an Open-Label Clinical Study of the Pharmacokinetics, Pharmacodynamics, Tolerability, Safety and Immunogenicity of Single Ascending Doses of BCD-131 in Healthy Volunteers

Detailed description: BCD-131 is novel drug product of pegylated darbepoetin alfa.

Clinical trial BCD-131-1 will be conducted in two stages:

Stage I is an open-label, non-randomized clinical study of pharmacokinetics, pharmacodynamics, tolerability, safety and immunogenicity of BCD-131 given to healthy volunteers at ascending doses (Phase 1, a traditional "3+3" design).

Also, the PK and PD parameters of the closest analogues of BCD-131 (Mircera and Aranesp) given as subcutaneous injections at therapeutic doses will be evaluated.

Stage II aims to further evaluate pharmacokinetics, pharmacodynamics and safety of subcutaneous and intravenous injections of BCD-131 at a dose which ensures PD effects similar to those of the closest analogues (Mircera, Aranesp) given as subcutaneous injections at therapeutic doses.

Eligibility criteria: Inclusion Criteria:

1. Signing of the Informed Consent Form;
2. Male sex;
3. Age of 18 to 45 years, inclusive;
4. BMI within normal limits (18.5-24.9 kg/m2);
5. Healthy patients, which is proved by their medical history, physical examination and laboratory findings:

   * No clinically significant abnormalities of circulatory, respiratory, nervous, hematopoietic, endocrine and digestive systems, liver and kidneys in the past medical history and at screening;
   * No history of cardiovascular disorders or thyroid disorders;
   * No history of hematologic disorders, including but not limited to any type of anemia, myelodysplastic syndrome, blood cancers, hemolytic syndrome, hemoglobinopathies, coagulopathies;
   * CBC results within normal limits, including:

     * Hemoglobin within 132-173 g/L;
     * Hematocrit (based on CBC results) within 39-49%;
     * Platelet count within 150-400\*109/L;
     * Absolute reticulocyte count within 30.4-93.5 \* 109/L;
   * Blood biochemistry and urinalysis results within normal limits;
   * Serum ferritin within 20-250 µg/L;
   * Serum endogenous erythropoietin within 4.3-29.0 MIU/mL;
   * Hemodynamic parameters within normal limits: systolic blood pressure within 100-139 mmHg; diastolic blood pressure within 60-90 mmHg; heart rate within 50-90 bpm;
   * No history of chronic infections (tuberculosis) or chronic inflammation;
   * No hepatitis B or C, HIV, or syphilis;
   * No acute infections within 4 weeks prior to inclusion in the study;
   * No psychiatric disorders and other conditions (including depression) that can interfere with the volunteer's ability to follow the study protocol;
   * Well-being (in the volunteer's opinion) within 30 days prior to inclusion in the study;
6. No history of or current (at baseline) alcohol or drug abuse;
7. Ability of the volunteer, in the investigator's opinion, to follow the study protocol procedures;
8. Willingness of volunteers and their sexual partners with preserved reproductive potential to use reliable contraception within 2 weeks before inclusion in the study and up to 7 weeks after the injection of the test product. This criterion is not applicable to subjects who underwent surgical sterilization. Reliable methods of contraception include one barrier method in combination with one of the following methods: spermicides, intrauterine device/oral contraceptives (for sexual partners).
9. Willingness of volunteers to avoid alcohol intake within 24 hours before and 8 days after each injection of the test drug;

Exclusion Criteria:

1. History of treatment with erythropoietins or any other ESAs;
2. Acute bleeding, blood/plasma donation or blood transfusion within 2 months before inclusion in the study;
3. History of chronic bleeding;
4. Standard laboratory and instrumental findings outside normal limits at screening;
5. History of allergies (anaphylactic shock or multiple drug allergy syndrome);
6. Known allergy or intolerance to any components of the investigational product;
7. Major surgery within 30 days prior to screening, or surgery being scheduled for any time during the study;
8. Impossibility to install a venous catheter for blood sampling (e.g. because of skin disorders at the sites of venipuncture);
9. Diseases or other conditions that can interfere with the pharmacokinetics of the investigational drug (e.g. chronic liver, kidney, blood, circulatory system, lung or neuroendocrine diseases, including diabetes mellitus and others);
10. History of fever of 40 °C or more;
11. History of elevated hepatic transaminases (above 2.5xULN);
12. Episodes of thrombosis and/or thromboembolia in past medical history (myocardial infarction, stroke, transient ischemic attacks, deep vein thrombosis, pulmonary embolism within 6 months prior to inclusion in the study) as well as an increased risk of deep vein thrombosis;
13. History of epileptic attacks or seizures;
14. History or current (at screening) depression, suicidal thoughts/ attempts;
15. Regular oral or parenteral use of any medications including over-the-counter drugs, vitamins and nutritional additives within 2 weeks before a scheduled injection of the test drug;
16. Use of drugs, including OTC products, that significantly affect the hemodynamics, hepatic function, etc. (barbiturates, omeprazole, cimetidine, etc.) within 30 days before a scheduled injection of the test drug;
17. Vaccination within 4 weeks before a scheduled injection of the test drug;
18. Smoking more than 10 cigarettes per day;
19. Consumption of more than 10 portions of alcohol per week (one portion equals to 0.5 L of beer, 200 mL of wine or 50 mL of ethanol) or a history of alcohol, drug or medication abuse;
20. Participation in other clinical studies within 1 month before screening or simultaneous participation in another clinical study;
21. Previous participation in this study.

Primary outcomes:
measure: AUC (0-1176 Hours)
timeFrame: 0, 15 min, 30 min; 60 min; 2 h, 4 h; 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 168 h, 216 h, 288 h, 336 h, 504 h, 672 h, 840 h, 1008 h, 1176 h post dose
Secondary outcomes:
measure: Cmax
timeFrame: 0, 15 min, 30 min; 60 min; 2 h, 4 h; 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 168 h, 216 h, 288 h, 336 h, 504 h, 672 h, 840 h, 1008 h, 1176 hours post-dose
measure: Tmax
timeFrame: 0, 15 min, 30 min; 60 min; 2 h, 4 h; 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 168 h, 216 h, 288 h, 336 h, 504 h, 672 h, 840 h, 1008 h, 1176 hours post-dose
measure: T1/2
timeFrame: 0, 15 min, 30 min; 60 min; 2 h, 4 h; 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 168 h, 216 h, 288 h, 336 h, 504 h, 672 h, 840 h, 1008 h, 1176 hours post-dose
measure: Kel
timeFrame: 0, 15 min, 30 min; 60 min; 2 h, 4 h; 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 168 h, 216 h, 288 h, 336 h, 504 h, 672 h, 840 h, 1008 h, 1176 hours post-dose
measure: Clearance of BCD-131
timeFrame: 0, 15 min, 30 min; 60 min; 2 h, 4 h; 8 h, 24 h, 48 h, 72 h, 96 h, 120 h, 168 h, 216 h, 288 h, 336 h, 504 h, 672 h, 840 h, 1008 h, 1176 hours post-dose
measure: AUEC (0-1176 Hours) - Reticulocytes
timeFrame: 0, 24 h, 48 h; 72 h; 96 h; 120 h; 168 h; 216 h; 288 h; 336 h, 504 h; 672 h; 840 h; 1008 h; 1176 h post-dose
measure: AUEC (0-1176 Hours) - Hemoglobin
timeFrame: 0, 24 h, 48 h; 72 h; 96 h; 120 h; 168 h; 216 h; 288 h; 336 h, 504 h; 672 h; 840 h; 1008 h; 1176 h post-dose
measure: AC-Emax - Reticulocytes
timeFrame: 0, 24 h, 48 h; 72 h; 96 h; 120 h; 168 h; 216 h; 288 h; 336 h, 504 h; 672 h; 840 h; 1008 h; 1176 h post-dose
measure: AC-Emax - Hemoglobin
timeFrame: 0, 24 h, 48 h; 72 h; 96 h; 120 h; 168 h; 216 h; 288 h; 336 h, 504 h; 672 h; 840 h; 1008 h; 1176 h post-dose
measure: Intensity of Pain After Subcutaneous Injection According to Visual Analog Scale
timeFrame: intraoperative
measure: Number of Participants With Adverse Events and Serious Adverse Events
timeFrame: from the first administartion of the drug up to the end of follow up period (28 days after the last dose of the drug)
measure: Number of Participants With Local Reactions
timeFrame: from the first administartion of the drug up to the end of follow up period (28 days after the last dose of the drug)
measure: Number of Participants With AE/SAE 3-4 Grade CTCAE
timeFrame: from the first administartion of the drug up to the end of follow up period (28 days after the last dose of the drug)
measure: Number of Participants With Early Withdrawal Due to AE
timeFrame: from the first administartion of the drug up to the end of follow up period (28 days after the last dose of the drug)
measure: Number of Participants With Binding Antibodies to BCD-131
timeFrame: 0, day 50 post-dose
Other outcomes:
Locations:
Study officials:
affiliation: JCS BIOCAD
name: Roman Ivanov, PhD
role: STUDY_CHAIR
References: